Boston Scien Cp Stock Price, News & Analysis

Boston Scientific Corporation (BSX) reported Q1 2022 net sales of $3.026 billion, reflecting a 10.0% increase year-over-year. GAAP net income was $97 million or $0.07 per share, down from $327 million or $0.23 per share a year ago. Adjusted EPS was $0.39, slightly up from $0.37. Growth was driven by all reportable segments, with notable increases in Cardiovascular (11.4%) and MedSurg (9.1%). However, GAAP EPS fell below the anticipated $0.16 to $0.20. The company remains optimistic for full-year growth despite macroeconomic challenges.

Boston Scientific Corporation (NYSE:BSX) will host a conference call on April 27, 2022, at 8:00 a.m. EDT, to discuss financial results for the first quarter ended March 31, 2022. The call will feature Mike Mahoney, CEO, and Dan Brennan, CFO, with a corresponding news release issued prior to the call. Interested parties can access the live webcast and replay at investors.bostonscientific.com.

Boston Scientific Corporation (NYSE:BSX) announced the pricing terms for its upsized cash tender offer totaling $2.85 billion for outstanding senior notes. The offer will expire on March 29, 2022 unless extended. Holders tendering before the Early Tender Date (March 15, 2022) may receive a $30 per $1,000 principal Early Tender Payment. These transactions are expected to be accretive to adjusted earnings per share by $0.02 in 2022, despite a projected $200 million charge on a GAAP basis.

Boston Scientific (BSX) announced results of its cash tender offer for up to $2.5 billion in senior notes, which received valid tenders of $5.139 billion by the early tender date of March 15, 2022. Due to high demand, the company has increased the maximum principal amount to $2.85 billion. The tender offer will expire on March 29, 2022. Holders of accepted securities will receive a $30 early tender payment and accrued interest.

Boston Scientific Corporation (NYSE: BSX) announced the completion of a €3.0 billion public offering of senior notes by its subsidiary, American Medical Systems Europe B.V. The offering includes various notes maturing from 2025 to 2034, with interest rates ranging from 0.750% to 1.875%. The net proceeds will fund a tender offer for up to $2.5 billion of senior notes and redeem certain existing notes. The company plans to use any remaining funds for debt repayment and general purposes, aiming to optimize its capital structure.

Boston Scientific Corporation (BSX) has priced a public offering of €3.0 billion in senior notes with various maturity dates from 2025 to 2034. The offering includes €1 billion of 0.750% notes due 2025 and additional notes due in later years with yields ranging from 1.375% to 1.875%. Proceeds will fund a $2.5 billion tender offer for existing senior notes and cover redemptions and associated costs. The offering is expected to close on March 8, 2022, subject to customary conditions.

Boston Scientific Corporation (BSX) has initiated a cash tender offer for up to $2.5 billion of its outstanding senior notes, as of March 2, 2022. The offer encompasses several series of notes with different maturity dates and acceptance prioritization. Tendering is open until March 29, 2022, with early tender benefits available until March 15, 2022. The company may redeem unpurchased notes subsequently. Barclays Capital, BofA Securities, and Citigroup Global Markets are managing the offer.

Boston Scientific announced promising results from the SURPASS analysis, evaluating real-world outcomes of the WATCHMAN FLX™ LAAC Device, at the CRT 2022 meeting. The study included over 16,000 patients with non-valvular atrial fibrillation. Key findings showed a low major adverse event rate of 0.37% at seven days post-implant, and only 0.28% of patients experienced ischemic stroke within 45 days. The device was successfully implanted in 97.6% of cases. Ongoing data collection through 2024 will further evaluate long-term outcomes.

Boston Scientific Corporation (BSX) has finalized its acquisition of Baylis Medical Company for $1.75 billion. This strategic move aims to enhance BSX's position in the growing cardiology market by integrating Baylis's advanced access solutions with BSX's existing electrophysiology and structural heart offerings. The acquisition is expected to be accretive to adjusted earnings per share starting in 2022, with potential for increased accretion subsequently. However, GAAP earnings may initially reflect dilution due to related expenses.